Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Enliven Therapeutics, Inc. (ELVN)

17.31   -0.78 (-4.31%) 05-31 13:20
Open: 17.98 Pre. Close: 18.09
High: 19.73 Low: 17.15
Volume: 48,638 Market Cap: 712(M)

Technical analysis

as of: 2023-05-31 12:47:38 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 23.24     One year: 25.22
Support: Support1: 17.14    Support2: 14.26
Resistance: Resistance1: 19.9    Resistance2: 21.6
Pivot: 19.55
Moving Average: MA(5): 18.87     MA(20): 19.47
MA(100): 15.1     MA(250): 7.54
MACD: MACD(12,26): -0.3     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 18.3     %D(3): 30.9
RSI: RSI(14): 35.8
52-week: High: 24.79  Low: 1
Average Vol(K): 3-Month: 124 (K)  10-Days: 124 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ELVN ] has closed below the lower bollinger band by 12.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.16 - 20.3 20.3 - 20.41
Low: 17.38 - 17.55 17.55 - 17.68
Close: 17.85 - 18.08 18.08 - 18.27

Company Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Headline News

Thu, 11 May 2023
Enliven Therapeutics Highlights Business Achievements and ... - GlobeNewswire

Tue, 11 Apr 2023
3 Stocks in the Limelight on New Analyst Coverage - Yahoo Finance

Thu, 23 Mar 2023
5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science - Yahoo Finance

Thu, 23 Mar 2023
Chronic Myeloid Leukemia Market to Exhibit Significant Growth as ... - GlobeNewswire

Fri, 03 Mar 2023
Veris Residential and Rogers Stock See Action From Activist Investors - Barron's

Thu, 23 Feb 2023
Enliven Therapeutics Closes Merger with Imara and Private ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 41 (M)
Shares Float 1 (M)
% Held by Insiders 2.8 (%)
% Held by Institutions 53.5 (%)
Shares Short 2,080 (K)
Shares Short P.Month 877 (K)

Stock Financials

EPS -0.93
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -6.35
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -24.7
Return on Equity (ttm) -42
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.94
Qtrly Earnings Growth 0
Operating Cash Flow -32 (M)
Levered Free Cash Flow -17 (M)

Stock Valuations

PE Ratio -18.81
PEG Ratio 0
Price to Book value -2.73
Price to Sales 0
Price to Cash Flow -22.17

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.